Pediatric Dermatology

Oleogel-10 exhibited potential to alleviate the physical, emotional, and economic strain of dressing changes, according to a poster presented at the SPD's annual meeting.

Tapinarof cream 1% has proven to be an effective and safe treatment for atopic dermatitis in diverse populations, according to a poster presented at the SPD's annual meeting.

TMB-001 0.05% demonstrates promising efficacy and safety in treating moderate to severe congenital ichthyosis, according to a poster presented at the SPD's annual meeting.

In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?

Nnena Agim, MD, presented a comprehensive update on non-steroidal topical therapies, highlighting off-label uses and recent FDA approvals in a session at the SPD's annual meeting.

Andrea Zaenglein, MD, discussed the role of patient counseling and addressing "hormone phobia" in young patients treated with hormonal therapies for acne in her SPD 2024 session.

Swanson discusses her SPD 2024 non-CME talk, expanding topical options for young patients, and more.

A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.

Paller discusses her SPD 2024 lecture, "Updates from ISSVA, ESPD, and SID: What You Missed that Could Change Your Practice."

Marissa Joseph, MD, discussed inflammatory hair disorders in young children, such as CCCA, in a presentation at the SPD's annual meeting.

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Lisa Weibel, MD, delved into skin signs of systemic diseases in the first of 2 Hurwitz lectures to be presented at the SPD's annual meeting.

Use of WoundSeal yielded no observed complications such as infection or bleeding, according to a poster presented at the SPD's annual meeting.

Hypertension and hyperlipidemia are common among obese pediatric patients with hidradenitis suppurativa, according to a poster presented at the SPD's annual meeting.

All domains of the DLQI and CDLQI experienced improvements through 108 weeks, according to a poster presented at the SPD's annual meeting.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Julapalli discusses her SPD 2024 lecture, "Rediscovering Joy in our Lives and the Workplace," excitement for the future of pediatric dermatology, and more.

The average pain score reported during treatment was 0.4/10, according to a poster presented at the SPD's annual meeting.

Mancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.

The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.

In a comparison of pediatric dermatologists versus AI, dermatologists primarily exhibited greater performance.

Researchers shared details of a noninvasive technique that detects abnormal inflammatory cytokine profiles in the skin of asymptomatic infant patients who subsequently develop AD.

The recommendations were recently published in JAMA Dermatology following an extensive literature review, article grading, and a review of research questions.

Swanson shared updates and a look ahead at what is in store for pediatric dermatology.

Burnett recently spoke with Dermatology Times to discuss the background, methods, and findings of the late-breaking INTEGUMENT-PED data, as well as its potential real-world and clinical implications.